© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Chloroquine phosphate has been around for decades. History shows how it once sat in medicine cabinets across the world, often as the go-to medicine for travelers heading to malaria-prone areas. The story goes back to the 1930s when German chemists first synthesized chloroquine as a less toxic alternative to quinine, which people had chewed from cinchona tree bark long before science refined treatment. Soldiers during World War II depended on it. Widespread malaria suppression programs in Africa and South America used chloroquine as a backbone. The world caught on quick that this drug wasn’t just affordable; it worked remarkably well for a long time.
Chloroquine phosphate looks pretty simple on the chemical drawing board, built around a 4-aminoquinoline nucleus. Its molecular formula—C18H26ClN3O·H3PO4—reveals a balance of carbon, nitrogen, and a phosphate group attached for the pharmaceutical salt. In pure form, it shows up as a white, bitter, crystalline powder. It dissolves easily in water and carries a distinct, medicinal taste. Yet, in practice, chemistry isn’t just about looks. The trick lies in its basic properties: it slips into the bloodstream and, inside red blood cells gnawed by the Plasmodium parasite, it blocks the process the parasite uses to clean up its own toxic waste, killing it from within. Drug resistance, though, is never far behind a medicine in continuous use, a reality that hit hard by the late 20th century.
Chloroquine’s preparation draws from organic synthesis rooted in the era of World War II industrial chemistry: starting with 4,7-dichloroquinoline and 4-diethylamino-1-methylbutylamine, bringing together two worlds of base chemical supply. Synthesizing the free base through a straightforward condensation, the process finishes by introducing phosphoric acid to deliver the phosphate salt. While this looks clean in textbooks, real-world production throws up hurdles of purity, scale-up, and operational safety. Nobody likes handling volatile solvents or choking on chemical dust. Proper ventilation and dosing accuracy matter every step. Manufacturing standards set by health authorities (think GMP guidelines) force producers to keep close records and stick to strict dosages. Labels must spell out both the chloroquine and salt content, warn about dosing in children, and mark expiration dates plainly.
On the global market, chloroquine phosphate shows up under multiple names—sometimes just “chloroquine” on old prescriptions, elsewhere as “Resochin” or “Aralen Phosphate.” These synonyms reflect decades of branded and generic cycles. Regardless of name, the drug’s profile doesn’t shift: it’s known as a 4-aminoquinoline antimalarial. Sometimes, the label lists it for autoimmune conditions like lupus and rheumatoid arthritis, based on its immune-suppressing side effects that, in some, become therapeutic.
Years of clinical experience show chloroquine isn’t just a cure-all. Toxicity risks demand respect—a truth hammered home in every pharmacology course. Swallowing too much, especially for kids, can bring on convulsions, cardiac arrest, and death. Even prescribed doses over time can build up in the retina, sometimes permanently damaging eyesight, or burden the liver in those who already have fragile organs. Health agencies, from the FDA to WHO, have flagged these issues—mandatory warnings, dosing limits, and regular vision checks form a basic framework for care. Misuse in the context of COVID-19 hammers home the danger of using powerful drugs without proper oversight. Reports of overdoses, cardiac-related deaths, and a global shortage for people with lupus serve as stark reminders of the stakes.
Malaria resistance sparked years of R&D, driving both chemical tweaks (modifying side chains, developing prodrugs) and trials pairing chloroquine with other drugs to stretch its utility. Labs tried to boost the molecule’s lifespan, adapt formulations for new delivery methods, or tackle tough strains in Africa and Southeast Asia. Researchers have also probed anti-cancer pathways, antiviral potential (beyond COVID-19), and ways to reduce long-term toxicity through altered dosing or co-administration. Not every experiment sticks, but the lessons keep medicine honest. Study after study reinforces a key point: every new claim about chloroquine needs the weight of real, reproducible evidence before practice changes.
The early phase of the COVID-19 pandemic thrust chloroquine phosphate into headlines, with some touting it as a silver bullet before large trials could catch up. It serves as a warning against the hype cycle in drug repurposing. Misapplied enthusiasm led to erratic purchasing, hoarding, and avoidable harm. Instead of a miracle, trials showed mixed and often disappointing results, with side effects sometimes outweighing modest benefit. Still, the pandemic left a mark: researchers saw firsthand how quickly old drugs can jump back into global consciousness, and how easily misinformation can upend medicine supply chains.
Looking forward, chloroquine phosphate still has a place in the antimalarial arsenal in regions with sensitive strains, though artemisinin-based combinations now lead the fight in much of Africa and Asia. Researchers continue to look for new uses and safer formulations, trying to separate useful immune-modulating effects from stubborn risks. Improved analogs and delivery tactics—slow-release implants, nanocarriers, smarter synthetic routes—sit on pharma’s “wish list.” Ensuring equitable access also means keeping prices fair, manufacturing standards high, and global stockpiles secure against the next health crisis. Above all, this drug’s journey teaches that medicine, for all its chemistry and history, plays out in real time among people making choices on the best available evidence. Science always moves forward, but only when myths give way to what the data prove, and safety guides every dose given.
Chloroquine phosphate has a long story tied to treating malaria. In places where mosquitoes spread this parasite, families keep a stash of these tablets, especially in rural villages across Africa and Asia. Chloroquine works by blocking the parasite from growing inside red blood cells, which keeps folks from falling seriously ill. It works best in regions where malaria hasn’t grown resistant, which still include parts of Central America and the Middle East, according to the World Health Organization.
Stories about chloroquine often resurface during global disease outbreaks. Early in the COVID-19 pandemic, heated debates filled the news—some voices pushed chloroquine as a quick solution. Many hoped it could help treat or even prevent the virus. The buzz got so loud that pharmacies in several countries ran low. Regulators and doctors later agreed the data just didn’t match the hype. Large trials, like those run by the National Institutes of Health, found no strong benefit for COVID-19 and real safety concerns, such as heart rhythm changes and vision problems.
Decades ago, some doctors also used chloroquine for rheumatoid arthritis and lupus. By quieting inflammation, it eases swollen joints and fatigue. Yet, newer medicines often bring better results and fewer side effects. Still, some stick with chloroquine, especially where access to other drugs stays limited or costs get in the way.
Nobody should take chloroquine lightly. Swallowing too much—even just a little over the prescribed dose—can cause trouble for the heart, eyes, and muscles. I’ve seen people come into the clinic after taking leftover pills from relatives. Some lost vision or ended up in the hospital. Regular eye checks and heart monitoring matter for those on long-term treatment. Mixing chloroquine with certain antidepressants and antibiotics can add risk.
Many people lean on older drugs because the alternatives price them out or just never reach their corner of the world. International aid programs, such as the Global Fund, still stock chloroquine for specific regions. But drug resistance threatens to shrink its usefulness. Each time malaria adapts, communities lose a cheap, familiar lifeline. My time working with rural clinics showed me how quickly stories circulate—word of success spreads, but so does rumor about miracle cures.
A big part of safer medicine comes down to education and supply chains. Folk wisdom can protect generations or put them at risk, if pills get shared without clear instructions. Training health workers and getting tested before taking treatment keeps resistance at bay. Governments and health agencies need to ramp up supplies of new drugs and lab tests, as this helps doctors pick the right tool for each disease stage.
Sticking with trusted, proven treatments protects more people than chasing the latest headline. Everyone deserves real information and affordable care. Figuring out what works best for local needs, while respecting proven science, helps whole communities stay ahead of the health curve.
Chloroquine phosphate stepped into the global spotlight during the COVID-19 panic. Many people started asking about its safety. It’s not a new drug. Doctors have given chloroquine for decades to treat malaria and some autoimmune diseases. That long history has shown both its good side and its darker side. Plainly put, chloroquine phosphate can bring relief, but it can also cause real trouble for the body, and this truth matters just as much today as ever.
I remember feeling relieved when a friend’s malaria symptoms faded after taking chloroquine. It felt safe back then, but the list of side effects left us all wary. The most reported issues start as stomach problems—nausea, vomiting, or diarrhea. These can hit hard enough to keep people from finishing a treatment course. Even with water and food, the discomfort can linger for hours, sometimes days.
Some notice changes in vision. This drug can collect in the eye, leading to what doctors call retinopathy. At first, it might just seem like blurry vision or trouble reading. Over time, vision can get much worse, even heading toward permanent damage if ignored or if the drug is used long-term for something like lupus. Regular eye checks help, but not everyone gets told about this risk from day one.
Pain in the chest, a racing heart, or an odd rhythm can raise alarms. Chloroquine can affect the heart’s electrical system, leading to a condition called QT prolongation. For people with certain heart conditions, or those who take other medicines that affect the heart, this risk grows. In a busy clinic, tracking down every possible drug interaction doesn’t always happen.
There is a risk for mental side effects too. Some people describe feeling confused or restless. I’ve seen others grow anxious or battle mood swings they’ve never felt before. Rarely, hallucinations creep in. I always tell friends to speak up if they feel “off” in their mind, even if it’s embarrassing.
Liver function tests can run off course while using this drug, especially with prolonged use. Rashes and itching sometimes follow, and in allergic cases, skin reactions can turn severe. There’s also a rare effect on blood counts—chilling news for anyone already facing illness. Doctors can track these changes with routine blood work, but labs cost money and time, and not every community clinic offers them often enough.
Facts matter more than hype. Study after study, including those from the World Health Organization, shows real side effects from chloroquine phosphate. No one should take new or unfamiliar medicines without a qualified doctor guiding the process. Side effects, no matter how rare, still happen to real people. Clear conversations and easy-to-read handouts can make all the difference. Only through honest discussion and patient safety practices can health systems support people who really need these medicines while protecting them from preventable harm.
Chloroquine phosphate gained attention as an old malaria drug thrown into the COVID-19 spotlight. Having lived through both the media chaos and watched family members who traveled struggle with malaria, I see how confusion can spiral quickly when a medication moves outside its main purpose. Chloroquine phosphate was built for malaria, not as a catch-all for every viral scare. The science behind its antiviral effects remains shaky—even experts at the World Health Organization echo this. Misinformation puts people at risk, especially when side effects creep in unnoticed.
Doctors spend years learning how each medication interacts with different bodies. In my own circle, I’ve seen folks tempted to self-treat after reading one too many online articles. Swallowing a pill like chloroquine phosphate without guidance often leads to trouble. Nausea, vision problems, and even heart rhythm issues pop up when the drug isn’t taken exactly as prescribed.
The U.S. Food and Drug Administration actually cautioned against unsupervised use for COVID-19. That speaks for itself—medications meant for special conditions can become dangerous in the wrong hands. Trusting your doctor isn’t just about safety, it’s also about getting honest information about whether the benefits outweigh the risks for your situation.
One memory stands out from my time spent traveling in regions with malaria risk. A doctor ran through the importance of sticking to a set schedule and taking the tablets with food. Missing a dose or doubling up if you forget means the medicine might cause more harm than good.
Chloroquine phosphate can build up in the body. The right amount keeps malaria at bay, but taking more won’t speed up recovery. In fact, the Centers for Disease Control and Prevention don’t mince words about overdose, which can be fatal—especially in children. Clear instructions often get written down by healthcare workers: frequency, duration, and what to do if side effects show up. Taking with food cuts down stomach upset, a tip that’s easy to overlook but makes the experience manageable.
Every person reacts differently. In my experience, folks taking other medications—especially those for heart conditions or immune issues—have run into trouble when chloroquine gets thrown into the mix. The drug can spark irregular heartbeats and make existing conditions worse. Regular check-ins with a doctor help spot trouble before it gets serious. Litmus tests and heart monitoring sometimes come into play for high-risk patients.
Vision problems or hearing changes show up rarely but can linger. Knowing the warning signs means you can bring them to your doctor early. Stopping the drug or swapping prescriptions usually sorts things out, but only under the advice of someone who knows your full medical history.
People need good information to make smart choices. Getting facts from trusted medical sources stops the spread of bad advice. Open conversations with healthcare providers give clarity, clear up rumors, and outline safe use. Pharmacies and clinics often hand out leaflets, but reading and asking questions matters just as much.
Safe medication use always starts and ends with guidance. Respect for a healthcare expert’s judgment and sticking to a prescribed regimen helps prevent unnecessary risks—something more important than ever in an age crowded with misinformation.
Few drugs have caught the public’s attention during the COVID-19 pandemic like chloroquine phosphate. In the early weeks, headlines painted it as a potential game-changer. People scrambled for tablets. Authorities stocked up. Some even risked self-medicating, chasing hope while experts warned about side effects. The whirlwind took off so fast because folks were desperate, not because real-world data backed anything up.
In my time following medical news, miracle cures come and go almost every year. Experience made me skeptical when claims about chloroquine’s power against novel viruses started popping up. Research does show chloroquine interferes with how some viruses enter cells. Lab tests hinted at possible benefits for COVID-19 early on. Stories from doctors in China and France made rounds on social media, fueling belief. But medicine shouldn’t run only on hope and anecdotes.
Well-controlled clinical trials cut through noise. And those trials, scattered across several continents, told a different story for chloroquine phosphate. One large study from Brazil testing high and low doses found no improved survival. Instead, patients faced heart rhythm problems. The World Health Organization stopped chloroquine arms in its Solidarity trial for that reason. I checked the published findings—knowing too well how fast facts can get twisted online. In all trustworthy analyses, chloroquine didn’t lower deaths, shorten hospital stays, or make symptoms clear up sooner.
People love a simple fix, especially during chaos. But skipping the real work undermines everybody. COVID-19 does plenty of harm already; adding risks from unproven treatments only makes things worse. Chloroquine is not new. Doctors have prescribed it for malaria and some autoimmune diseases for decades. That doesn’t mean it can stop a virus like SARS-CoV-2. In the US and elsewhere, poison control centers had to warn against misuse as hospitalizations from self-dosing spiked. Some pharmacies saw supply shortages, leaving lupus patients scrambling for what they needed most.
It’s tough for most people to sift through studies, jargon, and social media noise. Trust falls on local doctors, public health officials, and newsrooms who consistently check sources. With vaccines and specific antiviral drugs now backed by evidence, better options are here. People staying up to date on proven prevention—like vaccines, masking in crowds, and responsible testing—stay safer than those chasing miracle pills.
Medical teams shape their guidance from real numbers, not public buzz. One thing the chloroquine saga proves: we all benefit when governments and scientists communicate early and often, not just about what’s being tried, but what’s actually been proven. Each new crisis brings pressure to act fast, but skipping the science costs lives. Reliable communication and access to accurate data still beat viral hype and rumor every time.
Chloroquine phosphate used to show up in headlines during the early days of the COVID-19 pandemic. Some people thought of it as a miracle cure. In reality, this drug, originally made for treating malaria, carries serious risks for certain groups. I grew up in a family where stories about antimalarial drugs were common because my uncle traveled frequently for work. The advice was always clear: not everyone can use the same medicine safely. Chloroquine phosphate demands the same level of caution.
Anyone dealing with heart disease – including arrhythmias or heart failure – faces a big risk with this medication. Chloroquine phosphate can cause irregular heartbeats, sometimes deadly ones. The FDA and clinical guides warn about its potential to trigger QT prolongation, a problem that can set off torsades de pointes. As someone who knows a few older relatives on complex heart meds, I’ve seen how quickly drug side effects can stack up. For those with heart issues, adding chloroquine phosphate throws in more trouble than benefit.
Anyone with eye issues, especially those who already struggle with vision problems or have a history of retinopathy, stands at risk. Chloroquine phosphate is known for causing retinopathy that sometimes cannot be reversed. I’ve watched my neighbor, who suffered from lupus, spend years at the eye doctor after her medication set off new vision problems. For anyone with a retinal disorder, doctors shy away from this medication for a reason.
Small children, especially those under six years old, should not take chloroquine phosphate. Just a small amount can poison a child. Trying to get fancy with the dose is unsafe and irresponsible. On the other end, older adults may experience more side effects due to age-related changes in how their bodies handle drugs. They are more likely to have kidney or liver issues, both of which make it harder to clear chloroquine from the body.
Liver and kidney function affect how any drug moves through the body. Chloroquine phosphate puts a strain on both of these organs. If your body can't filter the drug out efficiently, it builds up and causes harm. Those with chronic kidney disease or any form of liver impairment face extra danger when using this drug. I’ve seen how my aunt, who struggled with kidney issues, would always double-check every prescription she received.
This medicine can stir up psychiatric symptoms, even in people with no prior history. In those who already struggle with anxiety, depression, or psychosis, the chances jump much higher. There are documented cases of people experiencing hallucinations or severe mood swings after starting chloroquine phosphate. These stories bring home the point: anybody with mental health struggles needs extra protection here.
Doctors should screen each patient for these health issues before writing a prescription. Anyone offered this drug deserves a real conversation about the risks, not just a quick list of side effects. Pharmacists also play a crucial role in flagging potential problems. Public health messaging can remind families to store these drugs far from children's reach and never share them. For people on multiple medications, carrying a current medication list, including supplements, helps prevent unintentional interactions.
| Names | |
| Preferred IUPAC name | phosphoric acid; N′,N′-diethyl-N-(7-chloroquinolin-4-yl)pentane-1,4-diamine |
| Other names |
Aralen Nivaquine Resochin CQ Chloroquine diphosphate |
| Pronunciation | /ˈklɔː.rə.kwiːn ˈfɒs.feɪt/ |
| Identifiers | |
| CAS Number | 50-63-5 |
| Beilstein Reference | 2346316 |
| ChEBI | CHEBI:3636 |
| ChEMBL | CHEMBL1200698 |
| ChemSpider | 15438 |
| DrugBank | DB00608 |
| ECHA InfoCard | 100.023.360 |
| EC Number | EC 231-299-8 |
| Gmelin Reference | 82730 |
| KEGG | D02366 |
| MeSH | D016559 |
| PubChem CID | 71832 |
| RTECS number | GQ9275000 |
| UNII | 6N9YKH5VQN |
| UN number | UN3151 |
| Properties | |
| Chemical formula | C18H26ClN3·H3PO4 |
| Molar mass | 515.86 g/mol |
| Appearance | White or almost white, crystalline powder |
| Odor | Odorless |
| Density | Density: 1.23 g/cm³ |
| Solubility in water | Soluble in water |
| log P | 4.63 |
| Acidity (pKa) | 8.4 |
| Basicity (pKb) | 9.1 |
| Magnetic susceptibility (χ) | -52.3×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.63 |
| Viscosity | Viscous liquid |
| Dipole moment | 7.7 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 427.51 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | –219.6 kJ/mol |
| Pharmacology | |
| ATC code | P01BA01 |
| Hazards | |
| Main hazards | Toxic if swallowed. Causes eye irritation. May cause allergic skin reaction. |
| GHS labelling | GHS05, GHS07, GHS08 |
| Pictograms | GHS06, GHS08 |
| Signal word | Danger |
| Hazard statements | H302 + H312 + H332: Harmful if swallowed, in contact with skin or if inhaled. |
| Precautionary statements | P202, P264, P270, P301+P312, P330, P501 |
| Flash point | > 218 °C (424 °F) |
| Autoignition temperature | 180°C |
| Lethal dose or concentration | LD50 (rat, oral): 2.13 g/kg |
| LD50 (median dose) | LD50 (median dose): 412 mg/kg (oral, rat) |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | 500 mg daily |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Chloroquine Hydroxychloroquine Amodiaquine Mefloquine Primaquine Quinine Quinacrine Pamaquine |
